Showing 1 - 2 results of 2 for search 'Minghai Tang', query time: 0.01s Refine Results
  1. 1
    CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury

    CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury by Yong Chen, Xue Yuan, Wei Yan, Yurong Zou, Haoche Wei, Yuhan Wei, Minghai Tang, Yulian Chen, Ziyan Ma, Tao Yang, Kongjun Liu, Baojian Xiong, Xiuying Hu, Jianhong Yang, Lijuan Chen

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma

    Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma by Linyu Yang, Qiang Qiu, Jie Wang, Yi Wen, He Li, Rui Liang, Yunyu Feng, Fang Wang, Xiaojing Lin, Minghai Tang, Jianhong Yang, Heying Pei, Peng Zhao, Jishi Wang, Jin Xiang, Jia Miao, Li Zheng, Ke Tan, Yongsheng Wang, Yiguo Hu, Lijuan Chen, Weili Zhao, Ting Niu

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: